Company / Return on Equity (ROE)
Xenetic Biosciences, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-65.9%
FY2025
5-year range
-89.2% / -30.7%
FY2021-FY2025
Trend
-56.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Xenetic Biosciences, Inc. reports negative total equity of -65.9% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-65.9% in FY2025 with a 5-year CAGR of +8.3%.
Declined from -48.0% to -65.9% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -35.2pp
- 5-Year Change
- +8.3pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 56.2% year-over-year.
- Peak return on equity (roe) was recorded in FY2018.
- Lowest return on equity (roe) in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -65.9% | -56.2% |
| FY2024 | -42.2% | +12.1% |
| FY2023 | -48.0% | -56.4% |
| FY2022 | -30.7% | +65.6% |
| FY2021 | -89.2% | -20.2% |
| FY2020 | -74.2% | -0.8% |
| FY2019 | -73.7% | -193.0% |
| FY2018 | -25.1% | +92.5% |
| FY2017 | -335.2% | -77.1% |
| FY2016 | -189.3% | -358.4% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026